IP Library › Granted Patent US 12,415,865
Granted Patent B2
US 12,415,865 · App. 18/478,846 · Granted Sep 16, 2025

Antibody molecules to C5AR1 and uses thereof

Inventors: Karthik Viswanathan (Waltham, MA); Brian Booth (Waltham, MA); Boopathy Ramakrishnan (Waltham, MA); Andrew Wollacott (Waltham, MA); Gregory Babcock (Waltham, MA); Zachary Shriver (Waltham, MA)
Assignee: Visterra, Inc.
C07K16/2896A61K2039/505C07K2317/31C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,865
App. No.
18/478,846
Granted
Sep 16, 2025
Kind
B2
Abstract

Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Claims (4)

1. A nucleic acid molecule comprising a nucleotide sequence encoding an antibody molecule that binds to complement component 5a receptor 1 (C5aR1), wherein the antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL),

wherein the VH comprises an HCDR1 comprising an amino acid sequence of SEQ ID NO: 612, an HCDR2 comprising an amino acid sequence of SEQ ID NO: 732, and an HCDR3 comprising and amino acid sequence of SEQ ID NO: 852, and

wherein the VL comprises an LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acid residues from SEQ ID NO: 672, an LCDR2 comprising an amino acid sequence of SEQ ID NO: 792, and an LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acid residues from SEQ ID NO: 912.

2. A host cell comprising the nucleic acid molecule of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: VISWANATHAN, KARTHIK; BOOTH, BRIAN; RAMAKRISHNAN, BOOPATHY; WOLLACOTT, ANDREW; BABCOCK, GREGORY; SHRIVER, ZACHARY
To: VISTERRA, INC.
Reel/Frame 065769/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2023
From: VISWANATHAN, KARTHIK; BOOTH, BRIAN; RAMAKRISHNAN, BOOPATHY; WOLLACOTT, ANDREW; BABCOCK, GREGORY; SHRIVER, ZACHARY
To: VISTERRA, INC.
Reel/Frame 065695/0289 →
Continuity (3)
Division 17147842 · Jan 13, 2021
Provisional Application 62960544 · Jan 13, 2020
Related Publication 20240150488A1 · May 9, 2024
References Cited (173)
US 5480974A · Morgan et al. · 1996 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7455837B2 · Guo et al. · 2008 [cited by applicant]
US 7632497B2 · Stavenhagen · 2009 [cited by applicant]
US 7863419B2 · Taylor et al. · 2011 [cited by applicant]
US 8071096B2 · Mackay · 2011 [cited by applicant]
US 8071839B2 · Mackay · 2011 [cited by applicant]
US 8084024B2 · Mackay · 2011 [cited by applicant]
US 8084582B2 · Dahiyat et al. · 2011 [cited by applicant]
US 8101720B2 · Lazar et al. · 2012 [cited by applicant]
US 8124731B2 · Lazar et al. · 2012 [cited by applicant]
US 8221757B2 · Mackay · 2012 [cited by applicant]
US 8268972B2 · Whitfeld et al. · 2012 [cited by applicant]
US 8318917B2 · Taylor et al. · 2012 [cited by applicant]
US 8337852B2 · Mackay · 2012 [cited by applicant]
US 8361468B2 · Whitfeld et al. · 2013 [cited by applicant]
US 8399618B2 · Lazar et al. · 2013 [cited by applicant]
US 8563259B2 · Lambris et al. · 2013 [cited by applicant]
US 8613926B2 · Kjaergaard et al. · 2013 [cited by applicant]
US 8673305B2 · Mackay · 2014 [cited by applicant]
US 8734791B2 · Lazar et al. · 2014 [cited by applicant]
US 8808701B2 · Whitfeld et al. · 2014 [cited by applicant]
US 8815237B2 · Wittrup et al. · 2014 [cited by applicant]
US 8846045B2 · Kjaergaard et al. · 2014 [cited by applicant]
US 8940299B2 · Medof et al. · 2015 [cited by applicant]
US 8952132B2 · Georgiou et al. · 2015 [cited by applicant]
US 8961967B2 · Strohl et al. · 2015 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9073983B2 · Guo et al. · 2015 [cited by applicant]
US 9180205B2 · Zeng et al. · 2015 [cited by applicant]
US 9458233B2 · Guo et al. · 2016 [cited by applicant]
US 9637549B2 · Strohl et al. · 2017 [cited by applicant]
US 9658236B2 · Mcknight et al. · 2017 [cited by applicant]
US 9683050B2 · Zeng et al. · 2017 [cited by applicant]
US 9790268B2 · Pan et al. · 2017 [cited by applicant]
US 9890218B2 · Mimoto et al. · 2018 [cited by applicant]
US 10053513B2 · Mccarthy et al. · 2018 [cited by applicant]
US 10183999B2 · Lazar et al. · 2019 [cited by applicant]
US 10323097B2 · Kjaergaard et al. · 2019 [cited by applicant]
US 10526408B2 · Georgiou et al. · 2020 [cited by applicant]
US 10590206B2 · Labrijn et al. · 2020 [cited by applicant]
US 10653791B2 · Lonberg et al. · 2020 [cited by applicant]
US 10774136B2 · Guo et al. · 2020 [cited by applicant]
US 10836813B2 · Pan et al. · 2020 [cited by applicant]
US 10882916B2 · Kjaergaard et al. · 2021 [cited by applicant]
US 10894836B2 · Stephen et al. · 2021 [cited by applicant]
US 11130801B2 · Medof et al. · 2021 [cited by applicant]
US 11142563B2 · Igawa et al. · 2021 [cited by applicant]
US 11912781B2 · Viswanathan et al. · 2024 [cited by applicant]
US 20040132101A1 · Lazar et al. · 2004 [cited by applicant]
US 20060235208A1 · Lazar et al. · 2006 [cited by applicant]
US 20110002931A1 · Tamburini · 2011 [cited by applicant]
US 20130295116A1 · Zahn et al. · 2013 [cited by applicant]
US 20140046032A1 · Blanche et al. · 2014 [cited by applicant]
US 20140105889A1 · Igawa et al. · 2014 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20180105600A1 · Pons et al. · 2018 [cited by applicant]
US 20180256646A1 · Medof et al. · 2018 [cited by applicant]
US 20180258161A1 · Igawa et al. · 2018 [cited by applicant]
US 20180282425A1 · Guo et al. · 2018 [cited by applicant]
US 20180319877A1 · Ruike et al. · 2018 [cited by applicant]
US 20190134020A1 · Deng et al. · 2019 [cited by applicant]
US 20190225708A1 · Bosteels et al. · 2019 [cited by applicant]
US 20190248897A1 · Ng et al. · 2019 [cited by applicant]
US 20190292269A1 · Monnet · 2019 [cited by applicant]
US 20190300621A1 · Ravetch et al. · 2019 [cited by applicant]
US 20200017598A1 · Andersson et al. · 2020 [cited by applicant]
US 20200095310A1 · Regula et al. · 2020 [cited by applicant]
US 20200131253A1 · Parren et al. · 2020 [cited by applicant]
US 20200148779A1 · Yamniuk et al. · 2020 [cited by applicant]
US 20200181257A1 · Kuramochi et al. · 2020 [cited by applicant]
US 20200199241A1 · Igawa et al. · 2020 [cited by applicant]
US 20200247897A1 · Jensen et al. · 2020 [cited by applicant]
US 20200299400A1 · Lonberg et al. · 2020 [cited by applicant]
US 20200316171A1 · Pandey · 2020 [cited by applicant]
US 20200332022A1 · Labrijn et al. · 2020 [cited by applicant]
US 20200376135A1 · Boitano et al. · 2020 [cited by applicant]
US 20210070860A1 · Marasco et al. · 2021 [cited by applicant]
US 20210070875A1 · Yang et al. · 2021 [cited by applicant]
US 20210238300A1 · Kjaergaard et al. · 2021 [cited by applicant]
US 20210261648A1 · Katada et al. · 2021 [cited by applicant]
US 20210285964A1 · Mcknight et al. · 2021 [cited by applicant]
US 20220135658A1 · Neugebauer et al. · 2022 [cited by applicant]
US 20220356263A1 · Viswanathan et al. · 2022 [cited by applicant]
US 20230365694A1 · Viswanathan · 2023 [cited by applicant]
CN 110072887A · 2019 [cited by applicant]
EP 1587540A2 · 2005 [cited by applicant]
EP 1443961B1 · 2009 [cited by applicant]
EP 1706424B1 · 2009 [cited by applicant]
EP 1701611B1 · 2011 [cited by applicant]
EP 1553975B1 · 2012 [cited by applicant]
EP 2679681A1 · 2014 [cited by applicant]
EP 2794658A1 · 2014 [cited by applicant]
EP 1476469B1 · 2015 [cited by applicant]
EP 2345671B1 · 2015 [cited by applicant]
EP 2940043A1 · 2015 [cited by applicant]
EP 2994488A1 · 2016 [cited by applicant]
EP 2506871B1 · 2016 [cited by applicant]
EP 2552955B1 · 2017 [cited by applicant]
EP 2673299B1 · 2017 [cited by applicant]
EP 2371861B1 · 2017 [cited by applicant]
EP 2486141B1 · 2018 [cited by applicant]
EP 2691417B1 · 2018 [cited by applicant]
EP 2718322B1 · 2018 [cited by applicant]
EP 3004174B1 · 2019 [cited by applicant]
EP 2844289B1 · 2019 [cited by applicant]
EP 3141260B1 · 2019 [cited by applicant]
EP 3541837A1 · 2019 [cited by applicant]
EP 3576793A1 · 2019 [cited by applicant]
EP 2943507B1 · 2020 [cited by applicant]
EP 3608339A1 · 2020 [cited by applicant]
EP 3630832A1 · 2020 [cited by applicant]
EP 3630833A1 · 2020 [cited by applicant]
EP 3424953B1 · 2020 [cited by applicant]
EP 2698431B1 · 2020 [cited by applicant]
EP 3768315A1 · 2021 [cited by applicant]
EP 3411400B1 · 2021 [cited by applicant]
IN 5572DELNP2010 · 2012 [cited by applicant]
JP 2010501164A · 2010 [cited by applicant]
JP 5162587B2 · 2012 [cited by applicant]
JP 2014523408A · 2014 [cited by applicant]
JP 2020524696A · 2020 [cited by applicant]
JP 2022524449A · 2022 [cited by applicant]
WO 9500164A1 · 1995 [cited by applicant]
WO 2004082568A3 · 2005 [cited by applicant]
WO 2005050199A1 · 2005 [cited by applicant]
WO 2008008482A2 · 2008 [cited by applicant]
WO 2008022390A1 · 2008 [cited by applicant]
WO 2008092117A2 · 2008 [cited by applicant]
WO 2009103113A1 · 2009 [cited by applicant]
WO 2011100477A2 · 2011 [cited by applicant]
WO 2012168199A1 · 2012 [cited by applicant]
WO 2018065389A1 · 2018 [cited by applicant]
WO 2018145075A1 · 2018 [cited by applicant]
WO 2018183520A1 · 2018 [cited by applicant]
WO 2018218056A1 · 2018 [cited by applicant]
WO 2018224609A1 · 2018 [cited by applicant]
WO 2018234118A1 · 2018 [cited by applicant]
WO 2018217988A9 · 2019 [cited by applicant]
WO 2019125846A1 · 2019 [cited by applicant]
WO 2019183362A1 · 2019 [cited by applicant]
WO 2020112781A1 · 2020 [cited by applicant]
WO 2020182974A1 · 2020 [cited by applicant]
WO 2021041715A2 · 2021 [cited by applicant]
WO 2021146320A1 · 2021 [cited by applicant]
WO 2021180063A1 · 2021 [cited by applicant]
WO 2021190770A1 · 2021 [cited by applicant]
Kussie et al., A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity, 1994, Journal of Immunology, pp. 146-152 (Year: 1994). [cited by examiner]
Vajdos et al, 2002, Comprehensive Functional Maps of the Antigen binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, 2002, Journal of Molecular Biology, vol. 320, pp. 415-428 (Year: 2002). [cited by examiner]
Brown et al., Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2, 1996, Journal of Immunology, vol. 156, pp. 3285-3291 (Year: 1996). [cited by examiner]
International Search Report and Written Opinion for PCT/US2022/012317 dated Jun. 17, 2022 (22 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/013284 dated May 4, 2021 (13 pages). [cited by applicant]
Akamizu et al., “Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity”, Clinical & Experimental Immunology, vol. 127, 200… [cited by applicant]
Anliker-Ort et al., “Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway”, Frontiers in Immunology, vol. 11, Article 599417, Dec. 2020, pp. 1-20, DOI: 10.3389/fimmu.2020.59941… [cited by applicant]
Bekker et al., “Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Pha… [cited by applicant]
Grayson et al., “Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis”, Seminars in Arthritis and Rheumatism, vol. 42, No. 3, Dec. 2011, pp. 424-433, DOI: 10.1016/j.semarthrit.2011.02.003, Autho… [cited by applicant]
Huang et al., “Discovery of human antibodies against the c5aR target using phage display technology”, Journal of Molecular Recognition, vol. 18, 2005, pp. 327-333, DOI: 10.1002/jmr.735 (7 pages). [cited by applicant]
Knight et al., “Late-onset neutropenia after rituximab in ANCA-associated vasculitis”, Scandinavian Journal of Rheumatology, vol. 45, No. 5, 2016, pp. 404-407, DOI: 10.3109/03009742.2016.1138318 (5 pages). [cited by applicant]
Kussie et al., “A single engineered amino acid substitution changes antibody fine specificity”, The Journal of Immunology, vol. 152, No. 1, Jan. 1994, pp. 146-152, DOI: 10.4049/jimmunol. 152.1.146 (8 pages). [cited by applicant]
La-Crette et al., “Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis”, Clinical Rheumatology, vol. 37, 2018, pp. 1085-1090, DOI: 10.1007/s10067… [cited by applicant]
Melis et al., “Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics”, Molecular Immunology, vol. 67, 2015, pp. 117-130, DOI: 10.1016/j.molimm.2015.01.028 (14 pages). [cited by applicant]
Ohlsson et al., “Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation”, PLOS One, vol. 14, No. 6, Jun. 19, … [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proceedings of the National Academy of Sciences USA, Immunology, vol. 79, Mar. 1982, pp. 1979-1983 (5 pages). [cited by applicant]
International Search Report for PCT/US2022/048609 dated Apr. 18, 2023 (10 pages). [cited by applicant]
Bertoglio, Frederico, et al., “A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations”, Dec. 3, 2020, retrieved on… [cited by applicant]
Bruhns, Pierre, et al., “Specificity and affinity of human Fcγ receptors and their polymorphic variants for human lgG subclasses”, Blood, vol. 113, No. 16, 2009, pp. 3716-3725, DOI: 10.1182/blood-2008-09-179754 (10 page… [cited by applicant]
Chenoweth, Alicia M, et al., “Harnessing the immune systems via FcyR function in immune therapy: a pathway to next-gen mAbs”, Immunology & Cell Biology, vol. 98, No. 4, 2020, pp. 287-304, DOI: 10.1111/IMCB.12326, (18 pa… [cited by applicant]
Ke, Shaoying, et al., “Expression of CD88 and its effect on invasiveness of gastric carcinoma”, Chinese Journal of Surgical Oncology, vol. 8, No. 3, Jun. 20, 2016 (4 pages). [cited by applicant]
Liu, Rena, et al., “Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment”, Antibodies, vol. 9, No. 4, 2020, 64, DOI: 10.3390/antib9040064, (34 pages). [cited by applicant]
Mehta, Guarav, et al., “A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA”, Journal of immunology (Baltimore, Md. : 1950), vol. 194, No. … [cited by applicant]
Morgan, E.L., et al., “Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor”, The Jo… [cited by applicant]
Mdarsson, Gestur, et al., “lgG subclasses and allotypes: from structure to effector functions”, Frontiers in Immunology, vol. 5, Article 520, 2014, DOI: 10.3389/fimmu.2014.00520, (17 pages). [cited by applicant]
Wang, Yu, et al., “Expression, Role, and Regulation of Neutrophil Fcγ Receptors”, Frontiers in Immunology, vol. 10, 2019, DOI: 10.3389/fimmu.2019.01958 (13 pages). [cited by applicant]